Merck & Co., Inc. Operating Lease Cost
Merck & Co., Inc. (MRK) reported Operating Lease Cost of $423.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-24
- Merck & Co., Inc. operating lease, cost for the quarter ending 2019-12-31 was $89.00M.
- Merck & Co., Inc. operating lease, cost for the quarter ending 2019-09-30 was $79.00M.
- Merck & Co., Inc. operating lease, cost for the quarter ending 2019-06-30 was $82.00M.
- Merck & Co., Inc. operating lease, cost for the quarter ending 2019-03-31 was $83.00M.
- Merck & Co., Inc. operating lease, cost for fiscal 2025 was $423.00M, a 21.55% increase from fiscal 2024.
- Merck & Co., Inc. operating lease, cost for fiscal 2024 was $348.00M, a 2.65% increase from fiscal 2023.
- Merck & Co., Inc. operating lease, cost for fiscal 2023 was $339.00M, a 1.50% increase from fiscal 2022.
- Merck & Co., Inc. operating lease, cost for fiscal 2022 was $334.00M, a 2.62% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $423.00M 10-K · filed 2026-02-24 | ||||
| 2024-12-31 | $348.00M 10-K · filed 2026-02-24 | ||||
| 2023-12-31 | $339.00M 10-K · filed 2026-02-24 | ||||
| 2022-12-31 | $334.00M 10-K · filed 2025-02-25 | ||||
| 2021-12-31 | $343.00M 10-K · filed 2024-02-26 | ||||
| 2020-12-31 | $340.00M 10-K · filed 2023-02-24 | $346.00M 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $89.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $168.00M derived: sum of 2 quarters · filed 2022-02-25 | $250.00M derived: sum of 3 quarters · filed 2022-02-25 | $333.00M 10-K · filed 2022-02-25 | $339.00M 10-K · filed 2020-02-26 |
| 2019-09-30 | $79.00M 10-Q · filed 2019-11-05 | $161.00M derived: sum of 2 quarters · filed 2019-11-05 | $244.00M 10-Q · filed 2019-11-05 | ||
| 2019-06-30 | $82.00M 10-Q · filed 2019-08-06 | $165.00M 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $83.00M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |